Login to Your Account

Clinic Roundup

Tuesday, October 18, 2011
Infinity Pharmaceuticals Inc., of Cambridge, Mass., completed enrollment in a Phase II trial of IPI-926 for pancreatic cancer. The trial has enrolled 122 patients and will compare IPI-926 in combination with gemcitabine to placebo and gemcitabine with a primary endpoint of overall survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription